tiprankstipranks
Advertisement
Advertisement

VALN Stock Latest News

Valneva Showcases Chikungunya Vaccine Progress at World Vaccine Congress in Washington
Company AnnouncementsValneva Showcases Chikungunya Vaccine Progress at World Vaccine Congress in Washington
7d ago
6K
VALN
Valneva and Pfizer Report Strong Phase 3 Efficacy for Lyme Disease Vaccine Candidate
PremiumCompany Announcements
Valneva and Pfizer Report Strong Phase 3 Efficacy for Lyme Disease Vaccine Candidate
10d ago
6K
VALN
Jefferies says Valneva stock weakness presents buying opportunity
PremiumThe Fly
Jefferies says Valneva stock weakness presents buying opportunity
10d ago
VALN
Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
PremiumMarket News
Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
10d ago
PFE
VALN
Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial
PremiumThe Fly
Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial
11d ago
PFE
VALN
Valneva Posts 2025 Results, Flags 2026 as Pivotal Year Ahead of Lyme Vaccine Phase 3 Data
PremiumCompany AnnouncementsValneva Posts 2025 Results, Flags 2026 as Pivotal Year Ahead of Lyme Vaccine Phase 3 Data
15d ago
6K
VALN
Elaris FlexCo secures exclusive global license from Valneva
Premium
The Fly
Elaris FlexCo secures exclusive global license from Valneva
15d ago
VALN
VALN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
VALN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
20d ago
VALN
Valneva Sets March 18 Date to Release Full-Year 2025 Results
PremiumCompany Announcements
Valneva Sets March 18 Date to Release Full-Year 2025 Results
24d ago
6K
VALN
Valneva Ramps Up Investor Outreach Ahead of Key Lyme Vaccine Data
PremiumCompany Announcements
Valneva Ramps Up Investor Outreach Ahead of Key Lyme Vaccine Data
1M ago
6K
VALN
Valneva Posts Stable 2025 Revenue, Sets 2026 Outlook Ahead of Key Lyme Vaccine Data
PremiumCompany Announcements
Valneva Posts Stable 2025 Revenue, Sets 2026 Outlook Ahead of Key Lyme Vaccine Data
1M ago
6K
VALN
Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile
PremiumCompany Announcements
Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile
2M ago
6K
VALN
Valneva and Instituto Butantan Launch Pilot Chikungunya Vaccination Campaign in Brazil
PremiumCompany AnnouncementsValneva and Instituto Butantan Launch Pilot Chikungunya Vaccination Campaign in Brazil
2M ago
6K
VALN
Valneva Withdraws U.S. IXCHIQ Chikungunya Filings After FDA Clinical Hold
Premium
Company Announcements
Valneva Withdraws U.S. IXCHIQ Chikungunya Filings After FDA Clinical Hold
2M ago
6K
VALN
Valneva withdraws BLA, IND application for Ixchiq in U.S.
Premium
The Fly
Valneva withdraws BLA, IND application for Ixchiq in U.S.
2M ago
VALN
Valneva to Engage Investors at J.P. Morgan Conference Ahead of Key Lyme Vaccine Data
PremiumCompany Announcements
Valneva to Engage Investors at J.P. Morgan Conference Ahead of Key Lyme Vaccine Data
3M ago
6K
VALN
Valneva Regains Full Rights to Chikungunya Vaccine as Serum Institute License Ends
PremiumCompany Announcements
Valneva Regains Full Rights to Chikungunya Vaccine as Serum Institute License Ends
3M ago
6K
VALN
Valneva, Serum Institute of India discontinue chikungunya vaccine pact
PremiumThe Fly
Valneva, Serum Institute of India discontinue chikungunya vaccine pact
3M ago
VALN
Valneva Reports Positive Phase 2 Results for Chikungunya Vaccine in Children
PremiumCompany Announcements
Valneva Reports Positive Phase 2 Results for Chikungunya Vaccine in Children
4M ago
6K
VALN
Valneva reports ‘positive’ final Phase 2 results for chikungunya vaccine
PremiumThe FlyValneva reports ‘positive’ final Phase 2 results for chikungunya vaccine
4M ago
VALN
Valneva Announces Strategic Consolidation of French Operations
Premium
Company Announcements
Valneva Announces Strategic Consolidation of French Operations
4M ago
6K
VALN
Valneva Reports Nine-Month 2025 Financial Results and Updates on Vaccine Developments
Premium
Company Announcements
Valneva Reports Nine-Month 2025 Financial Results and Updates on Vaccine Developments
4M ago
6K
VALN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >